AAAAAA

   
Results: 1-21 |
Results: 21
ANTITUMOR-ACTIVITY OF DAB(389)IL-2 FUSION TOXIN IN MYCOSIS-FUNGOIDES
Authors: SALEH MN LEMAISTRE CF KUZEL TM FOSS F PLATANIAS LC SCHWARTZ G RATAIN M ROOK A FREYTES CO CRAIG F REUBEN J SAMS MW NICHOLS JC
Citation: Mn. Saleh et al., ANTITUMOR-ACTIVITY OF DAB(389)IL-2 FUSION TOXIN IN MYCOSIS-FUNGOIDES, Journal of the American Academy of Dermatology, 39(1), 1998, pp. 63-73
PHASE-I TRIAL OF A LIGAND FUSION-PROTEIN (DAB(389)IL-2) IN LYMPHOMAS EXPRESSING THE RECEPTOR FOR INTERLEUKIN-2
Authors: LEMAISTRE CF SALEH MN KUZEL TM FOSS F PLATANIAS LC SCHWARTZ G RATAIN M ROOK A FREYTES CO CRAIG F REUBEN J NICHOLS JC
Citation: Cf. Lemaistre et al., PHASE-I TRIAL OF A LIGAND FUSION-PROTEIN (DAB(389)IL-2) IN LYMPHOMAS EXPRESSING THE RECEPTOR FOR INTERLEUKIN-2, Blood, 91(2), 1998, pp. 399-405
INTERLEUKIN-2 FUSION PROTEIN - AN INVESTIGATIONAL THERAPY FOR INTERLEUKIN-2 RECEPTOR-EXPRESSING MALIGNANCIES
Authors: NICHOLS J FOSS F KUZEL TM LEMAISTRE CF PLATANIAS L RATAIN MJ ROOK A SALEH M SCHWARTZ G
Citation: J. Nichols et al., INTERLEUKIN-2 FUSION PROTEIN - AN INVESTIGATIONAL THERAPY FOR INTERLEUKIN-2 RECEPTOR-EXPRESSING MALIGNANCIES, European journal of cancer, 33, 1997, pp. 34-36
PHASE-I TRIAL OF CORDYCEPIN AND DEOXYCOFORMYCIN IN TDT-POSITIVE ACUTE-LEUKEMIA
Authors: SELDIN DC LAHEY S URBANO A MCCAFFREY R FOSS F
Citation: Dc. Seldin et al., PHASE-I TRIAL OF CORDYCEPIN AND DEOXYCOFORMYCIN IN TDT-POSITIVE ACUTE-LEUKEMIA, Blood, 90(10), 1997, pp. 3847-3847
CHANGES IN QUALITY-OF-LIFE (QOL) FOR PATIENTS (PTS) ENROLLED IN A PHASE-III TRIAL OF TREATMENT WITH A DIPHTHERIA-TOXIN FUSION PROTEIN (DAB(389)IL-2) FOR MYCOSIS-FUNGOIDES (MF)
Authors: LIEPA A BENNETT CL YARNOLD PR ENAS N LOZANO J KUZEL T OLSON E MARTIN A KIM Y DUVIC M FRANKEL A VONDERHEID E BOWEN G JEGASOTHY B WOOD G GORDON M PINTERBROWN L FIVENSON D HEALD P OSCROFF A FOSS F GLODE M STEWART S MOLINA A KNOBLER E NICHOLS J
Citation: A. Liepa et al., CHANGES IN QUALITY-OF-LIFE (QOL) FOR PATIENTS (PTS) ENROLLED IN A PHASE-III TRIAL OF TREATMENT WITH A DIPHTHERIA-TOXIN FUSION PROTEIN (DAB(389)IL-2) FOR MYCOSIS-FUNGOIDES (MF), Blood, 90(10), 1997, pp. 3924-3924
DIGESTION OF TDT BY CASPASE-3 DURING APOPTOSIS
Authors: URBANO A OBREIN J MAGEE D LAHEY S FOSS F MCCAFFREY R
Citation: A. Urbano et al., DIGESTION OF TDT BY CASPASE-3 DURING APOPTOSIS, Blood, 90(10), 1997, pp. 208-208
ANTIBODY AND PHARMACOKINETIC ANALYSIS FROM A PIVOTAL TRIAL OF ONTAK(TM) (DAB(389)IL-2) FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL)
Authors: BACHA P FOWLIE A GRIMALDO D HILLIER J OLSEN E MARTIN A KIM Y DUVIC M FRANKEL A VONDERHEID E BOWEN G JEGASOTHY B WOOD G GORDON M PINTERBROWN L FIVENSON D HEALD P OSEROFF A KUZEL T FOSS F GLODE M STEWART S MOLINA A KNOBLER E
Citation: P. Bacha et al., ANTIBODY AND PHARMACOKINETIC ANALYSIS FROM A PIVOTAL TRIAL OF ONTAK(TM) (DAB(389)IL-2) FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL), Blood, 90(10), 1997, pp. 1457-1457
PIVOTAL PHASE-III TRIAL OF 2 DOSE LEVELS OF DAB(389)IL-2 (ONTAK(TM)) FOR THE TREATMENT OF MYCOSIS-FUNGOIDES (MF)
Authors: KUZEL T OLSEN E MARTIN A KIM Y DUVIC M FRANKEL A VONDERHEID E BOWEN G JEGASOTHY B WOOD G GORDON M PINTERBROWN L FIVENSON D HEALD P OSEROFF A FOSS F GLODE M STEWART S MOLINA A KNOBLER E NICHOLS J BACHA P
Citation: T. Kuzel et al., PIVOTAL PHASE-III TRIAL OF 2 DOSE LEVELS OF DAB(389)IL-2 (ONTAK(TM)) FOR THE TREATMENT OF MYCOSIS-FUNGOIDES (MF), Blood, 90(10), 1997, pp. 2607-2607
REGULATION OF NFKB-2 GENE-EXPRESSION IN T-LYMPHOMA CELLS
Authors: RABSON AB THAKUR S VIEIRA E LIN HC LIN J FOSS F
Citation: Ab. Rabson et al., REGULATION OF NFKB-2 GENE-EXPRESSION IN T-LYMPHOMA CELLS, The FASEB journal, 10(6), 1996, pp. 1570-1570
EFFECT OF DNA CONFORMATION ON CISPLATIN ADDUCT FORMATION
Authors: BUBLEY GJ XU J KUPIEC N SANDERS D FOSS F OBRIEN M EMI Y TEICHER BA PATIERNO SR
Citation: Gj. Bubley et al., EFFECT OF DNA CONFORMATION ON CISPLATIN ADDUCT FORMATION, Biochemical pharmacology, 51(5), 1996, pp. 717-721
IMMUNOPHENOTYPIC IDENTIFICATION OF SEZARY CELLS IN PERIPHERAL-BLOOD
Authors: BOGEN SA PELLEY D CHARIF M MCCUSKER M KOH H FOSS F GARIFALLOU M ARKIN C ZUCKERFRANKLIN D
Citation: Sa. Bogen et al., IMMUNOPHENOTYPIC IDENTIFICATION OF SEZARY CELLS IN PERIPHERAL-BLOOD, American journal of clinical pathology, 106(6), 1996, pp. 739-748
PRIMARY-CARE AND THE EDUCATION OF THE GENERALIST PHYSICIAN - COMING OF AGE - INTRODUCTION
Authors: RIVO ML ALTMAN D FOSS F
Citation: Ml. Rivo et al., PRIMARY-CARE AND THE EDUCATION OF THE GENERALIST PHYSICIAN - COMING OF AGE - INTRODUCTION, Academic medicine, 70(1), 1995, pp. 3-4
THE EFFECT OF ZANOTERONE, A STEROIDAL ANDROGEN RECEPTOR ANTAGONIST, IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
Authors: BERGER BM NAADIMUTKU A BODDY A FISHER HA MCCONNELL JD MILAM D MOBLEY D RAJFER J ADAMS G AIGEN AB BOYD S NARAYAN P ANDRIOLE G BAHNSON R BELVILLE W TOPLEY HM BLOCK N EPSTEIN HB LAZAN DW BAKULE PT BOYLE ET FERRIGNI R BRANNAN W BRAWER MK FOSS F COX CE SMITH J ELHILALI M GOLDENBERG L SULLIVAN L NORMAN R LAWEN JG TRACHTENBERG J LEPOR H KANDZARI S LABASKY R KALISH M PICKETT SH
Citation: Bm. Berger et al., THE EFFECT OF ZANOTERONE, A STEROIDAL ANDROGEN RECEPTOR ANTAGONIST, IN MEN WITH BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 154(3), 1995, pp. 1060-1064
EFFECTIVENESS OF TOPICAL NALOXONE, AN OPIOID ANTAGONIST, IN THE TREATMENT OF PRURITUS ASSOCIATED WITH MYCOSIS-FUNGOIDES (MF) AND SEZARY-SYNDROME (SS)
Authors: PINCUS S OSEROFF A BRENEMAN D FOSS F KOH H DUVIC M VONDERHEID E COE B PHILLIPS SB BERNSTEIN JE
Citation: S. Pincus et al., EFFECTIVENESS OF TOPICAL NALOXONE, AN OPIOID ANTAGONIST, IN THE TREATMENT OF PRURITUS ASSOCIATED WITH MYCOSIS-FUNGOIDES (MF) AND SEZARY-SYNDROME (SS), Journal of investigative dermatology, 104(4), 1995, pp. 661-661
PHASE-I TRIAL OF A DIPHTHERIA-TOXIN (DT) FUSION PROTEIN (DAB(389)IL-2) FOR THE TREATMENT OF INTERLEUKIN-2 RECEPTOR (IL-2R) EXPRESSING HEMATOLOGIC NEOPLASMS
Authors: KUZEL T FOSS F LEMAISTRE C PLATANIAS L RATAIN M ROOK A SALEH M SCHWARTZ G NICHOLS J
Citation: T. Kuzel et al., PHASE-I TRIAL OF A DIPHTHERIA-TOXIN (DT) FUSION PROTEIN (DAB(389)IL-2) FOR THE TREATMENT OF INTERLEUKIN-2 RECEPTOR (IL-2R) EXPRESSING HEMATOLOGIC NEOPLASMS, Blood, 86(10), 1995, pp. 1081-1081
IS CUTANEOUS T-CELL LYMPHOMA CURABLE
Authors: KOH HK JACOBSON JO FOSS F LEW RA
Citation: Hk. Koh et al., IS CUTANEOUS T-CELL LYMPHOMA CURABLE, Archives of dermatology, 131(9), 1995, pp. 1081-1082
REARRANGEMENT AND ALTERED EXPRESSION OF THE NFKB-2 GENE IN HUMAN CUTANEOUS T-LYMPHOMA CELLS
Authors: THAKUR S LIN HC TSENG WT KUMAR S BRAVO R FOSS F GELINAS C RABSON AB
Citation: S. Thakur et al., REARRANGEMENT AND ALTERED EXPRESSION OF THE NFKB-2 GENE IN HUMAN CUTANEOUS T-LYMPHOMA CELLS, Oncogene, 9(8), 1994, pp. 2335-2344
ARGININE BUTYRATE INDUCES APOPTOSIS IN SELECTED HEMATOPOIETIC TUMOR-CELL LINES
Authors: KOC Y MCCAFFREY R FOSS F
Citation: Y. Koc et al., ARGININE BUTYRATE INDUCES APOPTOSIS IN SELECTED HEMATOPOIETIC TUMOR-CELL LINES, Blood, 84(10), 1994, pp. 10000141-10000141
CORDYCEPIN ACTIVATES AN APOPTOTIC CASCADE IN TDT-POSITIVE LEUKEMIA-CELLS
Authors: KOC Y URBANO A SWEENEY E FOSS F MCCAFFREY R
Citation: Y. Koc et al., CORDYCEPIN ACTIVATES AN APOPTOTIC CASCADE IN TDT-POSITIVE LEUKEMIA-CELLS, Blood, 82(10), 1993, pp. 10000115-10000115
DAB389IL-2 IS WELL TOLERATED AT DOSES INDUCING RESPONSE IN IL-2 RECEPTOR-EXPRESSING LYMPHOMAS
Authors: LEMAISTRE CF KUZEL T FOSS F HESKETH P SALEH M PLATANIAS L SCHWARTZ G CRAIG F TOLSON K WOODWORTH T
Citation: Cf. Lemaistre et al., DAB389IL-2 IS WELL TOLERATED AT DOSES INDUCING RESPONSE IN IL-2 RECEPTOR-EXPRESSING LYMPHOMAS, Blood, 82(10), 1993, pp. 10000137-10000137
ANESTHESIA NOT RELATED TO FLUDARABINE TOXICITY - REPLY
Authors: COHEN RB FOSS F
Citation: Rb. Cohen et F. Foss, ANESTHESIA NOT RELATED TO FLUDARABINE TOXICITY - REPLY, Annals of internal medicine, 119(5), 1993, pp. 437-437
Risultati: 1-21 |